tbuckley/cabot-search huggingface dataset:
Abstract P173: Racial Differences in the Association Between Parity and Incident Stroke: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study
Authors: Catherine J Vladutiu, Michelle Snyder, Angela Malek, Alison M Stuebe, Aleena Mosher, Dawn Kleindorfer, Virginia J Howard
Journal: Circulation (2015)

Background:  Circulatory and vascular changes occurring during pregnancy may increase the risk of adverse cerebrovascular health outcomes in later life. Previous studies have examined the association between parity and stroke, but the results have been inconsistent. No studies have examined racial differences in this association.   Hypothesis:  We assessed the hypothesis that higher parity is associated with an increased risk of stroke and that this association varies by race in a large and diverse cohort of U.S. women.   Methods:  The association between parity and incident stroke was assessed among 8339 white and 7037 black women, aged 45 years and older, without a history of stroke who enrolled in the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study between 2003 and 2007. Parity was assessed at baseline and stroke cases were ascertained through biannual follow-up interviews and adjudicated with medical records through September 2013. Cox proportional hazards models were used to estimate hazard ratios (HR) for the association between parity and stroke, adjusting for baseline measures, including sociodemographics (age, race, education, marital status, income, region), behavioral characteristics (smoking, alcohol), reproductive history (menopause, oral contraceptive use, hormone replacement therapy), and stroke risk factors (history of hypertension, diabetes, and heart disease).   Results:  At baseline, 12.8% of white women and 16.2% of black women reported one prior live birth, while 8.1% and 19.0%, respectively, reported five or more prior live births. The mean follow-up time for all women was 6.9 years (SD=2.5) and there were 457 incident stroke cases (388 ischemic, 34 hemorrhagic, and 35 unknown stroke types). A significant interaction between race and parity was detected (p=0.05). Among white women, those with five or more live births had a higher risk of stroke than those with only one prior live birth (HR=1.3, 95% CI 0.8, 2.3), but the association was attenuated after adjustment for stroke risk factors and sociodemographic, behavioral, and reproductive characteristics (HR=0.9, 95% CI 0.5, 1.6). For black women, those with five or more live births had the highest risk of stroke as compared to those with only one prior live birth (HR=1.8, 95% CI 1.2, 2.8), but the association was attenuated and no longer statistically significant after adjustment for confounders (HR=1.5, 95% CI 0.9, 2.4).   Conclusion:  There were no statistically significant associations observed between higher parity and the risk of stroke in a diverse cohort of U.S. women. Further analyses are needed to elucidate the role of biological, lifestyle, and psychosocial factors in the race-specific associations that were observed.
Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD
Authors: Simona Zupo, Rosanna Massara, Mariella Dono, Edoardo Rossi, Fabio Malavasi, M. Elisabetta Cosulich, Manlio Ferrarini
Journal: Blood (2000)
SCV-07 treatment leads to alterations in VEGF, MIF, IL-1alpha, and MIP-1beta levels in patients with head and neck cancer
Authors: Cynthia W. Tuthill, Israel Rios, Katharina Modelska, Stephen T. Sonis, Edward Fey, Gil Alterovitz, Joel B. Epstein
Journal: Clinical Cancer Research (2010)

Abstract Introduction: Serum was collected before and after chemoradiation therapy from head and neck cancer (HNC) patients enrolled in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled trial designed to test the safety, tolerability and efficacy of an immunomodulatory peptide, gamma-D-glutamyl-L-tryptophan (SCV-07) as an intervention for oral mucositis (OM). Results of the trial demonstrated that the high dose of SCV-07 (0.1 mg/kg daily on days of radiation) was safe and effective in attenuating the course of OM. The objective of this study was to determine if the administration of high dose SCV-07 affected detectable levels of peripheral blood cytokines that may be involved in the host response to chemoradiation therapy for HNC. Experimental Procedures: Samples were analyzed via multiplex (Affymetrix Procarta cytokine assay), evaluating 35 proteins expected to be affected by SCV-07, which has been shown to stimulate a Th1 cytokine profile and to inhibit IL-6 dependent STAT3 signaling. For each of the 35 proteins, the null hypothesis “average subject protein value in high-dose regimen subjects equals average subject protein value in placebo regimen subjects” was tested against the alternative hypothesis “average subject protein value in high-dose regimen subjects does not equal average subject protein value in placebo regimen subjects.” A two tail test (=0.05) was used as there was no a priori knowledge of a relationship between protein levels and treatment regimen. Unequal population variances were assumed as the samples were not assumed to be random draws from the same population. The dataset analyzed 26 subjects given the high dose SCV-07 regimen and 23 subjects given placebo. Summary of Results: MIF, MIP-1beta, and VEGF were found to be significantly higher (p &amp;lt; 0.049, p &amp;lt; 0.049, p &amp;lt; 0.015 respectively) in high dose SCV-07 treated individuals compared to placebo, whereas IL-1alpha was found to be significantly lower (p &amp;lt; 0.045) in high dose SCV-07 treated individuals compared to placebo. Conclusions: SCV-07 treatment leads to increases in circulation of some immune-related cytokines (MIF, MIP-1beta, and VEGF) and leads to a decrease in another (IL-1alpha). These results can be used to better understand SCV-07's mechanism of action, and to follow biomarkers during future clinical trials evaluating SCV-07. Basic Research, Epigenetics, Immunology, Noncoding RNAs, Tumor Microenvironment, Metastasis, Target Identification, Validation, Lead Discovery, and Optimization
Obesity Prevention in the Information Age
Authors: Mark Berman, Risa Lavizzo-Mourey
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of serum hemoglobin (Hb) versus serum albumin (Alb) concentrations in estimating blood volume decrease during hemodialysis
Authors: D.J.W. van Kraaij, M.M.J. Schuurmans, I.H. Go, R.W.M.M. Jansen, W.H.L. Hoefnagels
Journal: Kidney International (1997)
Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis
Authors: J. M. Jensen, A. Scherer, C. Wanke, M. Bräutigam, S. Bongiovanni, M. Letzkus, F. Staedtler, J. Kehren, M. Zuehlsdorf, T. Schwarz, M. Weichenthal, R. Fölster‐Holst, E. Proksch
Journal: Allergy (2011)

Topical corticosteroids and calcineurin inhibitors are well-known treatments of atopic dermatitis (AD) but differ in their efficacy and side effects. We recently showed that betamethasone valerate (BM) although clinically more efficient impaired skin barrier repair in contrast to pimecrolimus in AD.This study elucidates the mode of action of topical BM and pimecrolimus cream in AD.Lesional AD skin samples after topical treatment with either BM or pimecrolimus were subjected to gene expression profile analysis.Betamethasone valerate resulted in a significant reduction in mRNA levels of genes encoding markers of immune cells and inflammation, dendritic cells, T cells, cytokines, chemokines, and serine proteases, whereas pimecrolimus exerted minor effects only. This corroborates the clinical finding that BM reduces inflammation more effectively than pimecrolimus. Genes encoding molecules important for skin barrier function were differently affected. Both BM and pimecrolimus normalized the expression of filaggrin and loricrin. BM, but not pimecrolimus, significantly reduced the expression of rate-limiting enzymes for lipid synthesis and the expression of involucrin and small proline-rich proteins, which covalently bind ceramides. This may explain the lack of restoration of functional stratum corneum layers observed after BM treatment.The gene expression profiles are consistent with our previous findings that corticosteroids may exert a more potent anti-inflammatory effect but may impair the restoration of the skin barrier. Corticosteroids are still the main treatment for severe and acutely exacerbated AD; pimecrolimus may be preferable for long-term treatment and stabilization.
Round About a Pound a Week
Authors: F. Wedgwood
Journal: BMJ (2011)

In 1909, Maud Pember Reeves and her colleagues in the Fabian Women’s Group started something extraordinary. Every week for four years these middle class women left the comforts of their Kensington homes and travelled to Lambeth Walk in south London. Their destinations were 42 households of poor, respectable, working class families, all of whom were living on round about a pound a week. Conceived as a sort of Edwardian Sure Start, the women recruited expectant mothers and gave them and their babies extra food.

The breathtaking aspect of their work was not their intervention but the data they captured in …
Abstract 2534: High-affinity small molecule inhibitors of the menin-MLL interaction reverse oncogenic transformation mediated by MLL fusion proteins in leukemia
Authors: Jolanta E. Grembecka, Shihan He, Timothy J. Senter, Dmitry Borkin, Jonathan Pollock, Changho Han, Sunil Kumar Upadhyay, Trupta Purohit, Hongzhi Miao, Rocco D. Gogliotti D. Gogliotti, Craig W. Lindsley, Tomasz Cierpicki, Shaun R. Stauffer
Journal: Cancer Research (2014)

Abstract The protein-protein interaction (PPI) between menin and Mixed Lineage Leukemia (MLL) plays a critical role in acute leukemias with translocations of MLL gene, and inhibition of this interaction with small molecules represents a new potential therapeutic strategy for the MLL leukemia patients. We identified novel small molecule inhibitors of the menin-MLL interaction with distinct molecular scaffolds by performing a High Throughput Screening (HTS) of over 300,000 compounds. Extensive medicinal chemistry efforts performed for two lead classes to improve inhibitory activity of these compounds resulted in menin-MLL inhibitors with low nanomolar binding affinities. The menin-inhibitor co-crystal structures revealed that these compounds directly bind to menin and closely mimic the key interactions of MLL with menin, resulting in their high binding affinity. Interestingly, the hydroxymethylpiperidine class of the menin-MLL inhibitors extends beyond the MLL binding region on menin, providing additional opportunity for their optimization. We combined extensive crystallography studies with structure-based design to perform rational optimization and scaffold modification to rapidly improve activity and modulate physicochemical properties of the menin-MLL inhibitors. Treatment of MLL leukemia cells with the most potent menin-MLL inhibitors we developed resulted in very effective and selective inhibition of cell proliferation, induced apoptosis and differentiation of these cells. These effects were associated with downregulation of Hoxa9 and Meis1 expression, the downstream targets of MLL fusion proteins required for their leukemogenicity, demonstrating a very specific mechanism of action for these newly developed menin-MLL inhibitors. In vivo studies are currently undergoing to assess the effect of these compounds on leukemia progression in animal models of MLL leukemia. Our studies provide a novel and very attractive scaffolds for further development as a new potential therapeutic approach for the MLL leukemia patients. Citation Format: Jolanta E. Grembecka, Shihan He, Timothy J. Senter, Dmitry Borkin, Jonathan Pollock, Changho Han, Sunil Kumar Upadhyay, Trupta Purohit, Hongzhi Miao, Rocco D. Gogliotti D. Gogliotti, Craig W. Lindsley, Tomasz Cierpicki, Shaun R. Stauffer. High-affinity small molecule inhibitors of the menin-MLL interaction reverse oncogenic transformation mediated by MLL fusion proteins in leukemia. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2534. doi:10.1158/1538-7445.AM2014-2534
Spontaneous Alveolar Rupture at Birth
Authors: V CHERNICK, M E AVERY
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 144: Salvage Peripheral Cardiopulmonary Support as a Bridge to Decision for Acute Refractory Cardiogenic Shock
Authors: Robert J Moraca, Kelly Wanamaker, Stephen H Bailey, Thomas D Maher, Walter E McGregor, Daniel Benckart, George J Magovern
Journal: Circulation (2011)

Objectives Acute refractory cardiogenic shock with early multisystem organ failure has a poor outcome without mechanical circulatory support. Emergent implantation of temporary or permanent central...
The Epidemiology of “Asymptomatic” Left Ventricular Systolic Dysfunction: Implications for Screening
Authors: Thomas J. Wang, Daniel Levy, Emelia J. Benjamin, Ramachandran S. Vasan
Journal: Annals of Internal Medicine (2003)

Congestive heart failure is a progressive disorder that is frequently preceded by asymptomatic left ventricular systolic dysfunction. We reviewed the epidemiology, diagnosis, and natural history of asymptomatic left ventricular systolic dysfunction and evaluated community-wide screening for this condition as a potential strategy to reduce the incidence of heart failure. Asymptomatic left ventricular systolic dysfunction has an estimated prevalence of 3% to 6%, and is at least as common in the community as systolic heart failure. Because it often occurs in the absence of known cardiovascular disease, this condition may go unrecognized and undertreated. In randomized trials, individuals with asymptomatic left ventricular systolic dysfunction have high rates of incident heart failure and death. However, little is known about the prognosis of individuals with this condition in the community, who have a substantially lower prevalence of myocardial infarction, have milder degrees of systolic dysfunction, and are older than patients enrolled in clinical trials. Current evidence is inadequate to support community-wide screening for asymptomatic left ventricular systolic dysfunction, either with echocardiography or with assays for natriuretic peptides. Given the increasing prevalence of heart failure, additional studies are needed to develop effective strategies to detect and optimally manage individuals with asymptomatic left ventricular dysfunction in the community.
Sarcoma Induced Remotely in Rats Fed 3-Methylcholanthrene
Authors: Charles Huggins, Lorraine C. Grand
Journal: Cancer Research (1963)

Repeated feeding of large but tolerable doses of 3-methylcholanthrene plus the reiterated injections in a given area of solutions of sesame oil or sodium chloride, with or without dissolved hormones, frequently evoked a fibrosarcoma at the injection site and only in this location in female albino rats.
Specialty Hospitals Generate Revenue and Controversy
Authors: Rebecca Voelker
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE USE OF NEOARSPHENAMINE IN THE TREATMENT OF AMEBIC DYSENTERY
Authors: James Graham Bruce
Journal: Annals of Internal Medicine (1946)

Article1 June 1946THE USE OF NEOARSPHENAMINE IN THE TREATMENT OF AMEBIC DYSENTERYJAMES GRAHAM BRUCEJAMES GRAHAM BRUCESearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-24-6-1025 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThis is to report 15 cases of amebic dysentery treated with neoarsphenamine intravenously during the Japanese internment of American Prisoners of War at Camp No. 1, Cabanatuan, Philippine Islands. This drug was not the drug of choice but rather the only drug at hand before the arrival of Red Cross medical supplies in December, 1943. Although neoarsphenamine had never been used to any appreciable extent for amebiasis, it was felt that the arsenic derived therefrom should be effective in eradicating the ameba and cysts. Arsenic is also a well known alterative, and it was believed that it would stimulate the...Bibliography1. BROWN PW: Results and dangers in treatment of amebiasis; summary of fifteen years' experience at Mayo Clinic, Jr. Am. Med. Assoc., 1935, cv, 1319. CrossrefGoogle Scholar2. ANDERSONCHUAN HHTT: Comparative amebicidal activity of phenyl arsine oxide (Mapharsen), related arsenicals and other agents, Am. Jr. Trop. Med., 1945, xxiv, 367. Google Scholar3. D'ANTONI JS: Personal communication. Google Scholar4. BASTEDO WA: Materia Medica, Pharmacology and Therapeutics, 1932, W. B. Saunders, Philadelphia, p. 626. Google Scholar5. EDMUNDSGUNN CWJA: Cushny's Pharmacology and Therapeutics, 1940, Lea and Febiger, Philadelphia, p. 204. Google Scholar6. KAGY ES: The amebiasis problem, Mil. Surg., 1939, lxxxiii, 158. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication October 18, 1945. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySubcutaneous emphysema and pneumomediastinum in diabetic keto-acidosisBook reviewRadionuclides in Medicine. By BarnabyC. F., pp. xiv+170 (illus.), 1969 (London, Souvenir Press Ltd.), £2·10. 1 June 1946Volume 24, Issue 6Page: 1025-1028KeywordsAmebiasisArsenicCyclic adenosine monophosphateDrugsDysentery ePublished: 1 December 2008 Issue Published: 1 June 1946 PDF downloadLoading ...
Physical Chemistry in the Service of Medicine. Seven addresses.
Authors: Wolfgang Pauli, Pauli Wolfgang, Martin Fischer
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal